A year ago Passage Bio launched with $115.5 million and plans to advance a handful of gene therapies discovered at the University of Pennsylvania.
Now the Philadelphia-based biotech is preparing to join the public markets and raise millions more to move its three lead programs into the clinic.
Passage, which has three preclinical programs and that many again in the discovery or candidate selection stage, set a $125 million target for its IPO, and said it plans to list on the Nasdaq under the stock symbol “PASG.”
Gene therapies use functioning genes, delivered within a modified virus or other “vector,” to… Read more »
UNDERWRITERS AND PARTNERS